ImpediMed Reports 3% Revenue Increase in Q4 FY26 Amid SOZO Platform's 95% National BCRL Reimbursement Coverage

SOZO Platform Growth Across US Hospitals and MSA Implementation

ImpediMed’s SOZO platform, a non-invasive bioelectrical impedance spectroscopy device for assessing body composition and fluid status, continues to expand within leading US healthcare institutions. Currently, 642 SOZO units are installed at major US hospitals, establishing a strong installed base to drive utilization and revenue growth. This network underpins the company’s multi-segment growth strategy, covering breast cancer-related lymphoedema, heart health, and emerging weight management applications.

The company reached an operational milestone by securing Master Services Agreements (MSAs) with 27 major Integrated Delivery Networks. These MSAs standardize IT approval processes, removing repetitive procurement obstacles and enabling clinical sales teams to swiftly access opportunities within these health systems. This framework accelerates adoption of SOZO for BCRL, Heart Health, and Body Composition applications by eliminating previous approval delays and facilitating faster clinical demand fulfillment.

Breast Cancer-Related Lymphoedema Reimbursement Coverage Hits 95% Nationwide

During Q4 FY26, reimbursement for SOZO in breast cancer-related lymphoedema treatment accelerated, with Medicare coverage reaching 95.0% nationally, covering 331 million lives—up from 94.3% in the prior quarter. Coverage above 95% now exists in 38 states, an increase from 37 states in Q3 FY26, while 47 states maintain coverage exceeding 90%, compared to 45 previously. This reimbursement growth supports new customer acquisition and re-engagement with existing hospital and health system accounts, as clinicians gain solid economic justification for SOZO deployment and expanded use.

The BCRL market opportunity is driven by evolving clinical consensus on cancer survivorship care. ImpediMed positions SOZO as a vital component of the patient journey from active cancer treatment through long-term survivorship monitoring. The platform offers objective, longitudinal measurement of body composition and fluid status, enabling early detection and intervention to prevent lymphoedema progression. This aligns with guidelines from the National Comprehensive Cancer Network and National Association of Prostate Cancer Boards, establishing a clinically validated pathway for wider adoption. The expanding reimbursement environment empowers commercial teams to increase utilization within existing accounts and accelerate new facility onboarding.

Cancer Survivorship Market Trends and Lymphedema+ Strategy

ImpediMed’s approach in the cancer survivorship segment reflects a shift in healthcare systems’ post-treatment patient care strategies. SOZO is positioned within a comprehensive wellness framework extending beyond lymphoedema surveillance to include lifestyle medicine, exercise oncology, and overall health outcome assessments. Management notes that over 60% of cancer survivors experience fear of recurrence, creating demand for objective assessments that offer reassurance and early warning. SOZO addresses this by serving as an objective tool for exercise oncology programs alongside lymphoedema screening, functioning as a comprehensive health monitoring solution within survivorship care.

The company employs a "land-and-expand" commercial strategy tailored to each Integrated Delivery Network and oncology partnership. Programs and pricing are customized based on patient flow, positioning SOZO as a strategic anchor in survivorship programs. This requires collaboration with breast surgeons, survivorship directors, oncology operations and finance leaders, and nurse navigators who facilitate patient adoption. The appointment of a new Customer Success leader focused on strategic accounts underscores management’s commitment to partnership development.

Heart Health Segment Infrastructure and Market Opportunity

The Heart Health segment offers significant long-term potential for ImpediMed, with a deliberate infrastructure-first approach rather than rapid customer acquisition. In Q4 FY26, the company established a dedicated clinical sales territory structure, conducted state-by-state reimbursement mapping for its HF-Dex application, and engaged cardiologists through structured surveys. These efforts aim to optimize HF-Dex positioning within clinical workflows and build the commercial foundation needed for scalable growth.

The US outpatient heart failure fluid monitoring market represents a $600 million total addressable market, driven by the need to reduce hospital readmissions and enable continuous body composition monitoring. Approximately 6.7 million Americans live with heart failure, with about 1 million new diagnoses annually. SOZO Pro is the only FDA-cleared bioelectrical impedance spectroscopy device approved for patients with cardiac implantable devices and benefits from a Medicare National Coverage Determination covering about 75% of Medicare heart failure patients. The company is pursuing FDA indication expansion to support broader clinical use, which management believes will accelerate cardiologist adoption once commercial infrastructure matures.

Weight Management and Body Composition Monitoring Pipeline

ImpediMed is gaining momentum in the Weight Management segment, with a robust pipeline of convertible sales leads across Primary Care, Sports Medicine and Research, Aesthetics and Med Spa, and Dedicated Weight Loss clinics. Body composition monitoring is a growing opportunity, especially as glucagon-like peptide-1 (GLP-1) therapies drive increased patient volumes through weight loss programs.

Clinicians increasingly recognize that weight alone is insufficient for evaluating GLP-1 treatment success. SOZO addresses this by providing precise body composition analysis that differentiates fat loss from lean muscle preservation, critical for assessing treatment efficacy and patient health. Providers seek objective, data-driven platforms that enhance client engagement, inform program decisions, and support long-term adherence. This evolving market dynamic fuels expanding adoption as GLP-1 therapy use grows across primary care, specialty weight loss, and aesthetics networks.

Quarterly Revenue and Recurring Revenue Growth

ImpediMed reported Q4 FY26 total revenue of $3.6 million, a 3% increase over Q3 FY26. Annual Recurring Revenue reached $14.4 million in reported currency, up 2% quarter-over-quarter. Adjusted for constant currency to remove foreign exchange effects, ARR was $14.6 million, reflecting 4% growth. This indicates underlying operational revenue growth outpaced reported figures, with Australian dollar depreciation impacting reported results.

SOZO Core Business Total Contract Value (TCV) was $5.4 million in Q4 FY26, stable from Q3 FY26 on a reported basis. On a constant currency basis, Core Business TCV rose 2%, suggesting stronger commercial performance masked by currency fluctuations. The company sold 36 SOZO units in the US during the quarter, contributing to the 642-unit installed base at leading hospitals. These metrics demonstrate effective execution of the commercial strategy amid currency headwinds and infrastructure investments.

Cash Flow and Capital Raise Highlights

Cash management improved significantly in Q4 FY26, with cash receipts increasing to $4.3 million, up $1.0 million from Q3 FY26. Net operating cash outflows were $4.9 million, rising $0.5 million quarter-over-quarter due to continued investment in commercial infrastructure and product development. The closing cash balance stood at $15.3 million as of 30 June 2026, bolstered by a $15.3 million capital raise and partial loan repayment of $5.0 million.

This capital raise enhances financial flexibility to invest in commercial infrastructure, particularly in early-stage Heart Health and Weight Management segments. Debt reduction lowers finance costs and strengthens the balance sheet, enabling future strategic investments. Improved cash receipts, capital infusion, and debt repayment provide a runway to execute the multi-segment growth strategy and meet operational targets. However, substantial operating cash outflows relative to revenue highlight the need for revenue acceleration and margin improvements.

Operating Cost Reduction Initiatives and Profitability Path

ImpediMed announced a $5.0 million annualized operating cost reduction program aimed at improving the path to profitability. Current operating cash outflows of approximately $4.9 million per quarter exceed revenue, making cost discipline essential. The planned reductions represent about 20% of estimated quarterly operating expenses, potentially improving cash burn if achieved without compromising commercial or product development investments.

The company intends to balance cost cuts with continued investment in strategic priorities, including customer success leadership, reimbursement mapping, and clinical relationship building. Management emphasizes maintaining growth initiatives while implementing cost controls. Successfully executing this balanced approach is critical to demonstrating sustainable profitability and maintaining investor confidence in long-term value creation.

Competitive Advantages and FDA Clearances

ImpediMed’s competitive edge is supported by unique FDA regulatory clearances and clinical validations. SOZO Pro is the only FDA-cleared bioelectrical impedance spectroscopy device approved for patients with cardiac implantable devices, providing a strong moat in the Heart Health segment. The company also holds FDA clearance for BCRL applications, backed by national Medicare reimbursement covering 95.0% of the population. These regulatory and reimbursement credentials create barriers to entry, support pricing power, and facilitate adoption within healthcare systems.

ImpediMed is pursuing expansion of FDA indication language to encompass broader clinical applications beyond initial clearances. This would enable SOZO to address a wider range of clinical scenarios and patient populations, unlocking additional market opportunities. The regulatory process involves clinical evidence generation and FDA engagement over multiple quarters, requiring sustained investment. Successful indication expansion could significantly increase the addressable market and leverage growth within the existing healthcare facility installed base.

Key Opinion Leader Engagement and Clinical Validation

The company’s commercial strategy includes structured engagement with Key Opinion Leaders (KOLs) across target specialties. Management reports recruiting "extremely passionate and well-known KOLs" to enhance clinical credibility and drive peer adoption in oncology and cardiology, where practitioner networks heavily influence uptake. Attracting high-profile clinical advocates strengthens SOZO’s value proposition and accelerates adoption within current and prospective customers.

ImpediMed’s KOL approach extends beyond traditional speaker roles to partnership models aligning incentives with SOZO adoption and utilization growth. KOLs actively participate in strategic account development and survivorship program customization, fostering durable clinical relationships. This collaboration provides valuable insights into clinical workflow integration, enabling continuous refinement of product positioning and commercial strategies based on real-world feedback and implementation experience.